Cargando…

Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.

Benzene exposure can cause leukemia, aplastic anemia, and possibly lymphoma. In 1978, on the basis of strong but incomplete data then available on the risk of benzene-induced leukemia, the U.S. Occupational Safety and Health Administration (OSHA) reduced the permissible occupational exposure standar...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicholson, W J, Landrigan, P J
Formato: Texto
Lenguaje:English
Publicado: 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568134/
https://www.ncbi.nlm.nih.gov/pubmed/2792039
_version_ 1782129948189786112
author Nicholson, W J
Landrigan, P J
author_facet Nicholson, W J
Landrigan, P J
author_sort Nicholson, W J
collection PubMed
description Benzene exposure can cause leukemia, aplastic anemia, and possibly lymphoma. In 1978, on the basis of strong but incomplete data then available on the risk of benzene-induced leukemia, the U.S. Occupational Safety and Health Administration (OSHA) reduced the permissible occupational exposure standard for benzene from 10 ppm to 1 ppm. Shortly thereafter, the Fifth Circuit Court of Appeals stayed this ruling, and in 1980, the Supreme Court overturned the regulation, citing insufficient evidence of benefit. Thus, from 1978 until the standard was again lowered to 1 ppm in 1987, American workers were exposed to benzene at levels in excess of 1 ppm. An estimated 9600 were exposed to levels between 1 and 10 ppm, and an additional 370 were exposed at levels above 10 ppm. To assess the risk resulting from this delay in regulation, we have conducted an epidemiologic risk analysis. We merged data on numbers of persons (238,000) exposed to benzene in seven occupational categories with dose-response data from three epidemiologic studies. The range of risk in these studies indicates that 44 to 152 excess leukemia deaths will ultimately result from exposure to benzene at 10 ppm over a working lifetime (45 years) and that lower or briefer exposures will result in proportionately fewer deaths. On this basis, we calculated that between 30 and 490 excess leukemia deaths will ultimately result from occupational exposures to benzene greater than 1 ppm that occurred between 1978 and 1987. Deaths from aplastic anemia and lymphoma will likely add to this toll. These data confirm the risk of regulatory delay. They suggest that the courts, in reviewing public health regulations, must beware of facile cost-benefit arguments and be willing to accept strong evidence of health risk even when such evidence is incomplete.
format Text
id pubmed-1568134
institution National Center for Biotechnology Information
language English
publishDate 1989
record_format MEDLINE/PubMed
spelling pubmed-15681342006-09-18 Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene. Nicholson, W J Landrigan, P J Environ Health Perspect Research Article Benzene exposure can cause leukemia, aplastic anemia, and possibly lymphoma. In 1978, on the basis of strong but incomplete data then available on the risk of benzene-induced leukemia, the U.S. Occupational Safety and Health Administration (OSHA) reduced the permissible occupational exposure standard for benzene from 10 ppm to 1 ppm. Shortly thereafter, the Fifth Circuit Court of Appeals stayed this ruling, and in 1980, the Supreme Court overturned the regulation, citing insufficient evidence of benefit. Thus, from 1978 until the standard was again lowered to 1 ppm in 1987, American workers were exposed to benzene at levels in excess of 1 ppm. An estimated 9600 were exposed to levels between 1 and 10 ppm, and an additional 370 were exposed at levels above 10 ppm. To assess the risk resulting from this delay in regulation, we have conducted an epidemiologic risk analysis. We merged data on numbers of persons (238,000) exposed to benzene in seven occupational categories with dose-response data from three epidemiologic studies. The range of risk in these studies indicates that 44 to 152 excess leukemia deaths will ultimately result from exposure to benzene at 10 ppm over a working lifetime (45 years) and that lower or briefer exposures will result in proportionately fewer deaths. On this basis, we calculated that between 30 and 490 excess leukemia deaths will ultimately result from occupational exposures to benzene greater than 1 ppm that occurred between 1978 and 1987. Deaths from aplastic anemia and lymphoma will likely add to this toll. These data confirm the risk of regulatory delay. They suggest that the courts, in reviewing public health regulations, must beware of facile cost-benefit arguments and be willing to accept strong evidence of health risk even when such evidence is incomplete. 1989-07 /pmc/articles/PMC1568134/ /pubmed/2792039 Text en
spellingShingle Research Article
Nicholson, W J
Landrigan, P J
Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
title Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
title_full Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
title_fullStr Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
title_full_unstemmed Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
title_short Quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
title_sort quantitative assessment of lives lost due to delay in the regulation of occupational exposure to benzene.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1568134/
https://www.ncbi.nlm.nih.gov/pubmed/2792039
work_keys_str_mv AT nicholsonwj quantitativeassessmentofliveslostduetodelayintheregulationofoccupationalexposuretobenzene
AT landriganpj quantitativeassessmentofliveslostduetodelayintheregulationofoccupationalexposuretobenzene